- Home
- EXC vs BDX Comparison
EXC vs BDX Comparison
Compare EXC & BDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EXC | BDX |
|---|---|---|
| Founded | 1999 | 1897 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Medical/Dental Instruments |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.4B | 43.0B |
| IPO Year | 2009 | 1998 |
Fundamental Metrics
Financial Performance| Metric | EXC | BDX |
|---|---|---|
| Price | $43.78 | $192.00 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 17 | 13 |
| Target Price | $50.59 | ★ $186.00 |
| AVG Volume (30 Days) | ★ 6.7M | 1.8M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.57% | 2.89% |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.90 | ★ 1.59 |
| Revenue | ★ $24,258,000,000.00 | $21,840,000,000.00 |
| Revenue This Year | $4.81 | N/A |
| Revenue Next Year | $3.25 | $3.02 |
| P/E Ratio | ★ $50.04 | $118.03 |
| Revenue Growth | 5.34 | ★ 8.24 |
| 52 Week Low | $42.58 | $140.11 |
| 52 Week High | $50.65 | $213.08 |
Technical Indicators
Market Signals| Indicator | EXC | BDX |
|---|---|---|
| Relative Strength Index (RSI) | 34.03 | 77.15 |
| Support Level | $43.09 | $190.78 |
| Resistance Level | $45.04 | $196.05 |
| Average True Range (ATR) | 0.87 | 4.38 |
| MACD | -0.11 | 0.75 |
| Stochastic Oscillator | 0.75 | 97.80 |
Price Performance
Historical ComparisonAbout EXC Exelon Corporation
Exelon serves approximately 10 million power and gas customers at its six regulated utilities in Illinois, Pennsylvania, Maryland, New Jersey, Delaware, and Washington, D.C.
About BDX Becton Dickinson and Company
Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.